InsiderClue
Stocks · Health care · Services-Commercial Physical & Biological Research

IB Acquisition Corp.

IBAC Clue Score35
United States Fiscal year ends September CIK 0001998781
$10.88 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $10.88 +4.11% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 May 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−0.0Net income−0.0Fiscal year 2024Operating income−0.5Net income1.9Fiscal year 2025Operating income−0.7Net income3.4 +82.9%
FY2023FY2024FY2025
Operating income −0.0 −0.5 −0.7
Net income −0.0 1.9 3.4
Growth +82.9%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−0.0Fiscal year 2024Operating cash flow−0.8Fiscal year 2025Operating cash flow−1.3Buybacks−106.1
FY2023FY2024FY2025
Operating cash flow −0.0 −0.8 −1.3
Buybacks n/a n/a −106.1

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.1Shareholders’ equity−0.0Fiscal year 2024Cash0.8Shareholders’ equity1.1Fiscal year 2025Cash0.4Shareholders’ equity−0.7
FY2023FY2024FY2025
Cash 0.1 0.8 0.4
Shareholders’ equity −0.0 1.1 −0.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending September, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 30 Sep 2023 FY2024 30 Sep 2024 FY2025 30 Sep 2025
Revenue and profit
0.0 0.5 0.7
−0.0 −0.5 −0.7
Growth
−0.0 2.5 4.4
n/a 0.6 1.0
−0.0 1.9 3.4
Growth +82.9%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 1 of 3 years on file.